Market Overview

Technical Take: Amicus Therapeutics Lower Despite Approval For Migalastat

Related FOLD
Amicus, Hasbro, Sears, And More: 'Fast Money Halftime Report' Final Picks
Jim Cramer Weighs In On PGT Innovations, Teck Resources And Amicus Therapeutics
ROTY Edition 1 Volume 71: Thoughts On A Juno Buyout, Outperformance Continues And Other Updates (Seeking Alpha)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) shares are trading lower by $1.78 (21 percent) at $6.54 in Tuesday's session. Although the company did receive FDA approval for Migalastat, Adam Feuerstein tweeted that the FDA wants more data and could cause a delay for the rollout of the drug until 2019.

Following a sharply lower open, the issue was trading in a fairly narrow range, with the current high standing at $6.74 and the current low standing at $6.30.

If the decline continues through the current low, there may be additional support at the pair of lows from November 3 ($5.82) and November 4 ($5.77). Those two lows provided the base for a rally that reached $9.61 on November 15.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (FOLD)

View Comments and Join the Discussion!